Tractocile

atosiban

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

What is Tractocile?

Tractocile is a solution for injection and a concentrate that is made up into a solution for infusion (drip into a vein). Both contain the active substance atosiban (7.5 mg per millilitre).

What is Tractocile used for?

Tractocile is used to delay birth in adult women who are 24 to 33 weeks pregnant, when they show signs that they may give birth pre-term (prematurely). These signs include:

  • regular contractions lasting at least 30 seconds at a rate of at least four every 30 minutes;
  • dilation of the cervix (the neck of the womb) of 1 to 3 cm and an effacement (a measure of the thinness of the cervix) of 50% or more.

In addition, the baby must have a normal heart rate.

The medicine can only be obtained with a prescription.

How is Tractocile used?

Treatment with Tractocile should be carried out by a doctor who has experience in the treatment of pre-term labour.

Treatment should be started as soon as possible after diagnosis of pre-term labour. Tractocile is given into a vein in three stages, over a maximum of 48 hours: an initial injection into a vein (6.75 mg), followed by a high-dose infusion (18 mg per hour) over three hours, then a lower dose infusion (6 mg per hour) lasting up to 45 hours. If contractions come back, treatment with Tractocile can be repeated up to three more times during the pregnancy.

How does Tractocile work?

The active substance in Tractocile, atosiban, is an antagonist of the natural hormone oxytocin. This means that atosiban blocks the action of oxytocin. Oxytocin is the hormone involved in starting contractions of the womb. By blocking the action of oxytocin, Tractocile prevents contractions and causes the womb to relax, helping to delay birth.

How has Tractocile been studied?

The ability of Tractocile to delay pre-term birth was studied in 742 women who were 23 to 33 weeks pregnant in three main studies. Tractocile was compared with ritodine, terbutaline and salbutamol (all from a different class of medicines used in pre-term labour called beta-agonists). The main measure of effectiveness was whether the treatment had worked after a week.

What benefit has Tractocile shown during the studies?

Looking at the results of the three main studies together, 60% of the women treated with Tractocile were still pregnant one week after treatment (201 out of 337) compared with 48% of the women treated with the comparator medicines (163 out of 342). There were too few women with a pregnancy at less than 28 weeks for the effectiveness of Tractocile in comparison to beta-agonists to be established in this group. The better result with Tractocile over the beta-agonists might have been because it caused fewer side effects, thereby allowing the patients to receive a full course of treatment.

What is the risk associated with Tractocile?

The most common side effect with Tractocile (seen in more than 1 patient in 10) is nausea (feeling sick). No side effects have been noted in the newborn baby. For the full list of all side effects reported with Tractocile, see the package leaflet.

Tractocile should not be used in people who may be hypersensitive (allergic) to atosiban or any of the other ingredients. It must not be used in women whose pregnancy is less than 24 weeks or more than 33 weeks, in women who have premature rupture of the membranes (when the waters break early) after 30 weeks of pregnancy, bleeding from the womb, eclampsia (a dangerous condition at the end of pregnancy caused by toxins in the blood), pre-eclampsia (a condition that can lead to eclampsia) or problems with the baby or placenta, or when continuing the pregnancy could be dangerous for the mother or baby. For the full list of restrictions, see the package leaflet.

Why has Tractocile been approved?

The Committee for Medicinal Products for Human Use (CHMP) concluded that Tractocile has shown an effectiveness in delaying pre-term birth that is the same as seen with beta-agonists, and that the better outcome with Tractocile was due to the medicine being better tolerated. The Committee decided that Tractocile’s benefits are greater than its risks and recommended that it be given marketing authorisation.

Other information about Tractocile

The European Commission granted a marketing authorisation valid throughout the European Union for Tractocile on 20 January 2000. The marketing authorisation holder is Ferring Pharmaceuticals A/S. The marketing authorisation is valid for an unlimited period.

Name Language First published Last updated
Tractocile : EPAR - Summary for the public BG = bălgarski 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public ES = español 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public CS = čeština 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public DA = dansk 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public DE = Deutsch 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public ET = eesti keel 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public EL = elliniká 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public EN = English 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public FR = français 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public IT = italiano 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public LV = latviešu valoda 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public LT = lietuvių kalba 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public HU = magyar 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public MT = Malti 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public NL = Nederlands 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public PL = polski 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public PT = português 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public RO = română 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public SK = slovenčina 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public SL = slovenščina 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public FI = suomi 27/03/2009 22/01/2010
Tractocile : EPAR - Summary for the public SV = svenska 27/03/2009 22/01/2010

This EPAR was last updated on 12/07/2016 .

Authorisation details

Product details

Product details for Tractocile
NameTractocile
Agency product numberEMEA/H/C/000253
Active substance

atosiban acetate

International non-proprietary name (INN) or common name

atosiban

Therapeutic area Premature Birth
Anatomical therapeutic chemical (ATC) code G02CX01

Publication details

Publication details for Tractocile
Marketing-authorisation holder

Ferring Pharmaceuticals A/S

Revision21
Date of issue of marketing authorisation valid throughout the European Union20/01/2000

Contact address:

Ferring Pharmaceuticals A/S
Kay Fiskers Plads 11
2300 København S
Denmark

Product information

Product information

23/06/2016  Tractocile -EMEA/H/C/000253 -N/0065

Name Language First published Last updated
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016
Tractocile : EPAR - Product Information SV = svenska 07/07/2009 12/07/2016

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010
Tractocile : EPAR - All Authorised presentations SV = svenska 15/08/2006 22/01/2010

Pharmacotherapeutic group

Other gynaecologicals

Therapeutic indication

Tractotile is indicated to delay imminent pre-term birth in pregnant adult women with:

  • regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes;
  • a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50%;
  • a gestational age from 24 until 33 completed weeks;
  • a normal foetal heart rate.

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated
Tractocile : EPAR - Procedural steps taken and scientific information after authorisation SV = svenska 07/07/2009 12/07/2016

Initial marketing-authorisation documents

Name Language First published Last updated
Tractocile : EPAR - Procedural steps taken before authorisation SV = svenska 15/08/2006  
Tractocile : EPAR - Scientific Discussion SV = svenska 15/08/2006  

Authorised

This medicine is approved for use in the European Union